Dr. Ron’s Research Review – August 21, 2013

© 2013

This week’s research review focuses on berberine for metabolic syndrome.

A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with a diagnosis of metabolic syndrome.

Twelve patients received berberine hydrochloride (500 mg) three times daily before meals for 3 months. The remaining 12 patients received placebo.

Administration of berberine leads to remission of metabolic syndrome in 36% (P=0.037) and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity. (AUC = area under the curve)

waist circumference in females, cm

106+/-4

103+/-3

P<0.05

systolic BP, mmHg

123+/-7

115+/-9

P<0.01

triglycerides, mmol/L

2.4+/-0.7

1.4+/-0.5

P<0.01

AUC of glucose, mmol/L

1182.1+/-253.6

1069.5+/-172.4

P<0.05

AUC of insulin, mmol/L

92,056+/-72,148

67,407+/-46,441

P<0.01

insulinogenic index, pmol/L

0.78+/-0.69

0.62+/-0.46

P<0.05

Matsuda index

2.1+/-1.0

3.1+/-1.6

P<0.01

 

Dr. Ron


Article

Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

         (Perez-Rubio, Gonzalez-Ortiz et al. 2013) Download

Abstract Background: The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with a diagnosis of metabolic syndrome. Glucose and insulin levels after a dextrose load were measured. Triglycerides and high-density lipoprotein cholesterol concentrations at baseline were also measured. Twelve patients received berberine hydrochloride (500 mg) three times daily before meals for 3 months. The remaining 12 patients received placebo. Area under the curve (AUC) of glucose and insulin, total insulin secretion, first-phase of insulin secretion, and insulin sensitivity were assessed. Results: After berberine administration, patients had a remission of 36% (P=0.037) in the presence of metabolic syndrome and a significant decrease in waist circumference in females (106+/-4 vs. 103+/-3 cm, P<0.05), systolic blood pressure (SBP) (123+/-7 vs. 115+/-9 mmHg, P<0.01), triglycerides (2.4+/-0.7 vs. 1.4+/-0.5 mmol/L, P<0.01), area under the curve (AUC) of glucose (1182.1+/-253.6 vs. 1069.5+/-172.4 mmol/l, P<0.05), AUC of insulin (92,056+/-72,148 vs. 67,407+/-46,441 pmol/L, P<0.01), and insulinogenic index (0.78+/-0.69 vs. 0.62+/-0.46, P<0.05), as well as an increase in the Matsuda index (2.1+/-1.0 vs. 3.1+/-1.6, P<0.01). Conclusions: Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.

Reference

Perez-Rubio, K. G., M. Gonzalez-Ortiz, et al. (2013). "Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion." Metab Syndr Relat Disord. [PMID: 23808999]